Travere Therapeutics Shares Are Trading Higher After Wedbush Maintained an Outperform Rating on the Stock and Raised Its Price Target From $17 to $25.
Travere Therapeutics Shares Are Trading Higher After Wedbush Maintained an Outperform Rating on the Stock and Raised Its Price Target From $17 to $25.
Travere Therapeutics股票交易價格上漲，Wedbush維持其股票的表現評級，並將其目標價格從17美元提高至25美元。
Travere Therapeutics Shares Are Trading Higher After Wedbush Maintained an Outperform Rating on the Stock and Raised Its Price Target From $17 to $25.
Travere Therapeutics股價上漲，Wedbush維持其股票買入評級並將目標股價從17美元上調至25美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間